Marwan Fakih, MD; Jaideep Sandhu, MBBS, MPH; Dean Lim, MD; et al.
free access
JAMA Oncol. 2023;9(5):627-634. doi:10.1001/jamaoncol.2022.7845
This nonrandomized clinical trial assesses the recommended phase 2 dose of regorafenib, ipilimumab, and nivolumab immunotherapy for patients with refractory microsatellite stable metastatic colorectal cancer.
Irbaz Bin Riaz, MD, PhD; Syed Arsalan Ahmed Naqvi, MBBS; Huan He, PhD; et al.
free access
JAMA Oncol. 2023;9(5):635-645. doi:10.1001/jamaoncol.2022.7762
This systematic review and meta-analysis investigates the comparative effectiveness of triplet therapy vs androgen pathway inhibitors doublet therapy for patients with heterogeneous metastatic castration-sensitive prostate cancer.
Dian Wang, MD; Jonathan Harris, MS; William G. Kraybill, MD; et al.
free access
has audio
JAMA Oncol. 2023;9(5):646-655. doi:10.1001/jamaoncol.2023.0042
This ancillary analysis of 2 randomized clinical trials of patients receiving neoadjuvant chemoradiotherapy or preoperative image-guided radiotherapy examines the prognostic significance of pathologic complete response on survival outcomes in patients with soft tissue sarcoma receiving neoadjuvant chemoradiotherapy.
-
Podcast:
Pathologic Complete Response and Clinical Outcomes in Soft Tissue Sarcoma
Roberta Sanfilippo, MD; Nadia Hindi, MD; Josefina Cruz Jurado, MD; et al.
free access
JAMA Oncol. 2023;9(5):656-663. doi:10.1001/jamaoncol.2023.0056
This nonrandomized clinical trial investigates the safety and effectiveness of trabectedin with radiotherapy in patients with myxoid liposarcoma.
Davide Serrano, MD; Sara Gandini, PhD; Parjhitham Thomas, MD; et al.
free access
JAMA Oncol. 2023;9(5):664-672. doi:10.1001/jamaoncol.2023.0089
This randomized clinical trial compares exemestane, 25 mg, given once daily, 3 times weekly, and once weekly for the treatment of estrogen receptor鈥損ositive breast cancer in postmenopausal women prior to surgery.
Susana Banerjee, MBBS, MA, PhD; Gaia Giannone, MD; Andrew R. Clamp, BMBCh, MSc, PhD; et al.
open access
JAMA Oncol. 2023;9(5):675-682. doi:10.1001/jamaoncol.2022.7966
This phase 2 randomized clinical trial evaluates whether the addition of vistusertib to weekly paclitaxel improves clinical outcomes in patients with platinum-resistant ovarian high-grade serous carcinoma.
Locke J. Bryan, MD; Carla Casulo, MD; Pamela B. Allen, MD; et al.
free access
JAMA Oncol. 2023;9(5):683-691. doi:10.1001/jamaoncol.2022.7975
This nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed or refractory Hodgkin lymphoma.
Jaewon Hyung, MD; Ilhwan Kim, MD; Kyu-pyo Kim, MD; et al.
free access
JAMA Oncol. 2023;9(5):692-699. doi:10.1001/jamaoncol.2023.0016
This randomized clinical trial examines the addition of treatment with liposomal irinotecan to fluorouracil and leucovorin for patients with advanced biliary tract cancer.